Zeitschrift für Rheumatologie

, Volume 76, Supplement 3, pp 77–104 | Cite as

S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

  • Jan Henrik Schirmer
  • Peer M. Aries
  • Kirsten de Groot
  • Bernhard Hellmich
  • Julia U. Holle
  • Christian Kneitz
  • Ina Kötter
  • Peter Lamprecht
  • Ulf Müller-Ladner
  • Eva Reinhold-Keller
  • Christof Specker
  • Michael Zänker
  • Frank Moosig
Leitlinien
  • 38 Downloads

S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

Die Autoren geben folgende mögliche Interessenkonflikte an: P.M. Aries – Beratertätigkeit für Roche und Medac; Vortragshonorare: Roche; Mitgliedschaften: BDRh, DGRh; Arbeitgeber: Selbstständigkeit. K. de Groot – Mitglied des Sicherheitskommittees der PRIMAVERA-Studie (Roche), Vortragshonorare: AbbVie, Avigen, Berlin Chemie, Bristol-Myers Squibb, Merck, MSD, Pfizer, UCB; Arbeitgeber: Sana Klinikum Offenbach, Kuratorium für Dialyse und Nierentransplantation e.V. B. Hellmich – Beratertätigkeit für Celgene, GSK, Medac, Roche; Vortragshonorare: AbbVie, Bristol-Myers Squibb, Celgene, Chugai, Novartis, Pfizer, Roche; Honorare für die Teilnahme an multizentrischen klinischen Studien (nicht persönlich, sondern an die Klinik): Ab2Bio, AbbVie, AstraZeneca, GSK, Novartis, Pfizer, Roche; Mitgliedschaften: ACR, DGIM, DGRh, EUVAS, Koautorenschaft der EULAR-Recommendations für Vaskulitiden; Arbeitgeber: Medius Kliniken gGmbH, Kirchheim unter Teck. J.U. Holle – Mitgliedschaften: DGIM, DGRh, BDRh; Beratertätigkeit: Lilly; Vortragshonorare: Chugai, Lilly, Roche; Finanzierung von Symposien: AbbVie, Actelion, Biogen, BMS, Celgene, Chugai, GSK, Lilly, Medac, Novartis, MSD, UCB; Arbeitgeber: Selbstständigkeit; ehemals Klinikum Bad Bramstedt. C. Kneitz – Berater‑/Gutachtertätigkeit für AbbVie, Celgene, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi; Vortragshonorare: AbbVie, Berlin Chemie, Chugai, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, UCB; Drittmittel für Forschungsvorhaben oder direkte Finanzierung von Mitarbeitern: Pfizer; Mitgliedschaften: BDRh, DGRh, DGIM, VRA; Arbeitgeber: Klinikum Südstadt Rostock. I. Kötter – Vortragshonorare: AbbVie, Actelion, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Pfizer, Roche, UCB; Mitgliedschaften: DGIM, DGRh; Arbeitgeber: Asklepios Klinik Altona. P. Lamprecht – Berater‑/Gutachtertätigkeit für Chugai, Roche; Vortragshonorare: Chugai, Janssen, Novartis, Roche; persönliche Beziehungen zu einem Vertretungsberechtigten eines Unternehmens der Gesundheitswirtschaft; Arbeitgeber: Universitätsklinikum Schleswig-Holstein, Campus Lübeck. F. Moosig – Beratertätigkeit für Chugai, Lilly, Roche; Vortragshonorare: Chugai, Lilly, Pfizer, Roche; Drittmittel für Forschungsvorhaben: Chugai, Pfizer; Finanzierung von Symposien: AbbVie, Actelion, Biogen, BMS, Celgene, Chugai, GSK, Lilly, Medac, Novartis, MSD, UCB; Mitgliedschaften: DGIM, DGRh, RSM, EUVAS, BDRh; Arbeitgeber: Selbstständigkeit, ehem. Klinikum Bad Bramstedt. U. Müller-Ladner – Berater‑/Gutachtertätigkeit für Chugai, Medac, Pfizer, Roche; Vortragshonorare: Chugai, Medac, Pfizer, Roche; Drittmittel für Forschungsvorhaben oder direkte Finanzierung von Mitarbeitern: Chugai, Roche; Mitgliedschaften: ACR, DGIM, DGRh, EULAR; Arbeitgeber: Justus-Liebig-Universität Gießen, Kerckhoff Klinik Bad Nauheim. E. Reinhold-Keller – Vortragshonorare: Berlin Chemie, Pfizer, Roche; Mitgliedschaften: DGIM, DGRh; Arbeitgeber: Selbstständigkeit. J.H. Schirmer – Honorar für Schulungstätigkeit: Actelion; Mitgliedschaften: DGIM, DGRh, EUVAS; Arbeitgeber: Universitätsklinikum Schleswig-Holstein, Campus Kiel; ehemals: Klinikum Bad Bramstedt, Universitätsklinikum Schleswig-Holstein, Campus Lübeck. C. Specker – Berater‑/Gutachtertätigkeit für AbbVie, Boehringer, Janssen, Lilly, MSD, Novartis, UBC; Vortragshonorare: AbbVie, Chugai, Celgene, MSD, Novartis, Pfizer, UCB; Drittmittel für Forschungsvorhaben oder direkte Finanzierung von Mitarbeitern: Chugai; Mitgliedschaften: DGRh; Arbeitgeber: St. Josef Krankenhaus, Universitätsklinikum Essen. M. Zänker – Beratertätigkeit für Celgene, Hospira, MSD, Roche; Vortragshonorare: Celgene; Mitgliedschaften: BDRh, DGRh; Arbeitgeber: Immanuel Klinikum Bernau Herzzentrum Brandenburg.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Aasarød K, Iversen BM, Hammerstrøm J et al (2000) Wegener’s granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 15:611–618PubMedCrossRefGoogle Scholar
  2. 2.
    Aasarød K, Bostad L, Hammerstrøm J et al (2001) Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrol Dial Transplant 16:953–960PubMedCrossRefGoogle Scholar
  3. 3.
    Abdou NI, Kullman GJ, Hoffman GS et al (2002) Wegener’s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 29:309–316PubMedGoogle Scholar
  4. 4.
    Agency for Health Care Policy and Research, Department of Health and Human Services (1992) Acute pain management: operative or medical procedures and trauma. Clinical practice guideline, Bd. no. 1. AHCPR Publ, Rockv, S 100–107Google Scholar
  5. 5.
    Alberici F, Smith RM, Jones RB et al (2014) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keu452 Google Scholar
  6. 6.
    Allen A, Pusey C, Gaskin G (1998) Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 9:1258–1263PubMedGoogle Scholar
  7. 7.
    Allenbach Y, Seror R, Pagnoux C et al (2009) High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 68:564–567. https://doi.org/10.1136/ard.2008.099051 PubMedCrossRefGoogle Scholar
  8. 8.
    Arbach O, Gross WL, Gause A (2002) Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 206:496–501PubMedCrossRefGoogle Scholar
  9. 9.
    Arebro J, Henriksson G, Macchiarini P, Juto J‑E (2012) New treatment of subglottic stenosis due to Wegener’s granulomatosis. Acta Otolaryngol 132:995–1001. https://doi.org/10.3109/00016489.2012.674213 PubMedCrossRefGoogle Scholar
  10. 10.
    van Assen S, Agmon-Levin N, Elkayam O et al (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70:414–422. https://doi.org/10.1136/ard.2010.137216 PubMedCrossRefGoogle Scholar
  11. 11.
    Azar L, Springer J, Langford CA, Hoffman GS (2014) Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener’s): a retrospective single-center study. Arthritis Rheumatol 66:2862–2870. https://doi.org/10.1002/art.38744 PubMedCrossRefGoogle Scholar
  12. 12.
    Basu N, McClean A, Harper L et al (2014) The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis 73:207–211. https://doi.org/10.1136/annrheumdis-2012-202750 PubMedCrossRefGoogle Scholar
  13. 13.
    Berden AE, Ferrario F, Hagen EC et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21:1628–1636. https://doi.org/10.1681/ASN.2010050477 PubMedCrossRefGoogle Scholar
  14. 14.
    Besada E, Koldingsnes W, Nossent JC (2013) Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology (Oxford) 52:2041–2047. https://doi.org/10.1093/rheumatology/ket257 CrossRefGoogle Scholar
  15. 15.
    Besada E, Koldingsnes W, Nossent JC (2014) Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 53:1818–1824. https://doi.org/10.1093/rheumatology/keu194 CrossRefGoogle Scholar
  16. 16.
    Bingham CO, Looney RJ, Deodhar A et al (2010) Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62:64–74. https://doi.org/10.1002/art.25034 PubMedCrossRefGoogle Scholar
  17. 17.
    Birck R, Warnatz K, Lorenz HM et al (2003) 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14:440–447PubMedCrossRefGoogle Scholar
  18. 18.
    Boomsma MM, Stegeman CA, van der Leij MJ et al (2000) Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43:2025–2033.https://doi.org/10.1002/1529-0131(200009)43:9〈2025::AID-ANR13〉3.0.CO;2-OPubMedCrossRefGoogle Scholar
  19. 19.
    Boomsma MM, Stegeman CA, Kramer AB et al (2002) Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos Int 13:74–82PubMedCrossRefGoogle Scholar
  20. 20.
    Booth AD, Almond MK, Burns A et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776–784PubMedCrossRefGoogle Scholar
  21. 21.
    Bourgarit A, Le Toumelin P, Pagnoux C et al (2005) Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84:323–330CrossRefGoogle Scholar
  22. 22.
    Bremer JP, Ullrich S, Laudien M et al (2010) Methotrexate plus leflunomide for the treatment of relapsingWegener’s granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol 28:67–71PubMedGoogle Scholar
  23. 23.
    Cannady SB, Batra PS, Koening C et al (2009) Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope 119:757–761. https://doi.org/10.1002/lary.20161 PubMedCrossRefGoogle Scholar
  24. 24.
    Carlson JA, Chen K‑R (2006) Cutaneous vasculitis update: small vessel neutrophilic vasculitis syndromes. Am J Dermatopathol 28:486–506. https://doi.org/10.1097/01.dad.0000246646.45651.a2 PubMedCrossRefGoogle Scholar
  25. 25.
    Carpenter DM, Thorpe CT, Lewis M et al (2009) Health-related quality of life for patients with vasculitis and their spouses. Arthritis Rheum 61:259–265. https://doi.org/10.1002/art.24235 PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Cartin-Ceba R, Keogh KA, Specks U et al (2011) Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 26:2865–2871. https://doi.org/10.1093/ndt/gfq852 PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Cartin-Ceba R, Golbin JM, Keogh KA et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum 64:3770–3778. https://doi.org/10.1002/art.34584 PubMedCrossRefGoogle Scholar
  28. 28.
    Cartin-Ceba R, Diaz-Caballero L, Alqadi MO et al (2015) Diffuse alveolar hemorrhage secondary to ANCA-associated vasculitis: predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol. https://doi.org/10.1002/art.39562 Google Scholar
  29. 29.
    Charles P, Néel A, Tieulié N et al (2014) Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford) 53:532–539. https://doi.org/10.1093/rheumatology/ket381 CrossRefGoogle Scholar
  30. 30.
    Chocova Z, Hruskova Z, Mareckova H et al (2015) Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters. Clin Rheumatol 34:107–115. https://doi.org/10.1007/s10067-014-2816-7 PubMedCrossRefGoogle Scholar
  31. 31.
    Clowse MEB, Behera MA, Anders CK et al (2009) Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health 18:311–319. https://doi.org/10.1089/jwh.2008.0857 CrossRefGoogle Scholar
  32. 32.
    Clowse MEB, Copland SC, Hsieh T‑C et al (2011) Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res 63:1777–1781. https://doi.org/10.1002/acr.20605 CrossRefGoogle Scholar
  33. 33.
    Comarmond C, Pagnoux C, Khellaf M et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270–281. https://doi.org/10.1002/art.37721 PubMedCrossRefGoogle Scholar
  34. 34.
    Congdon D, Sherris DA, Specks U, McDonald T (2002) Long-term follow-up of repair of external nasal deformities in patients with Wegener’s granulomatosis. Laryngoscope 112:731–737. https://doi.org/10.1097/00005537-200204000-00025 PubMedCrossRefGoogle Scholar
  35. 35.
    Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Lerma-Márquez JL (2011) Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. Rheumatology (Oxford) 50:1414–1423. https://doi.org/10.1093/rheumatology/ker112 CrossRefGoogle Scholar
  36. 36.
    Crickx E, Machelart I, Lazaro E et al (2016) Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French nationwide study of ninety-two patients. Arthritis Rheumatol 68:702–712. https://doi.org/10.1002/art.39472 PubMedCrossRefGoogle Scholar
  37. 37.
    Danieli MG, Cappelli M, Malcangi G et al (2004) Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 63:1649–1654. https://doi.org/10.1136/ard.2003.015453 PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Daoud MS, Gibson LE, DeRemee RA et al (1994) Cutaneous Wegener’s granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol 31:605–612PubMedCrossRefGoogle Scholar
  39. 39.
    DeRemee RA, McDonald TJ, Harrison EG, Coles DT (1976) Wegener’s granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin Proc 51:777–781PubMedGoogle Scholar
  40. 40.
    Devaney KO, Travis WD, Hoffman G et al (1990) Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 14:555–564PubMedCrossRefGoogle Scholar
  41. 41.
    Effelsberg N, Warnatz K, Peter H et al (2011) Treatment with rituximab induces a severe decrease in immunogloubline levels in patients with ANCA positive vasculitis. Ann Rheum Dis 70(Suppl3):623Google Scholar
  42. 42.
    Elmedhem A, Adu D, Savage COS (2003) Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 18:1001–1004PubMedCrossRefGoogle Scholar
  43. 43.
    de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group) (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16:2018–2027PubMedCrossRefGoogle Scholar
  44. 44.
    Exley AR, Bacon PA, Luqmani RA et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371–380PubMedCrossRefGoogle Scholar
  45. 45.
    Fauci AS, Katz P, Haynes BF, Wolff SM (1979) Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301:235–238. https://doi.org/10.1056/NEJM197908023010503 PubMedCrossRefGoogle Scholar
  46. 46.
    Faurschou M, Sorensen IJ, Mellemkjaer L et al (2008) Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35:100–105PubMedGoogle Scholar
  47. 47.
    Faurschou M, Mellemkjaer L, Sorensen IJ et al (2009) Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 60:1187–1192. https://doi.org/10.1002/art.24386 PubMedCrossRefGoogle Scholar
  48. 48.
    Faurschou M, Westman K, Rasmussen N et al (2012) Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3472–3477. https://doi.org/10.1002/art.34547 PubMedCrossRefGoogle Scholar
  49. 49.
    Faurschou M, Obel N, Baslund B (2014) High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res 66:1910–1914. https://doi.org/10.1002/acr.22423 CrossRefGoogle Scholar
  50. 50.
    Finkielman JD, Merkel PA, Schroeder D et al (2007) Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147:611–619PubMedCrossRefGoogle Scholar
  51. 51.
    Flossmann O, Bacon P, de Groot K et al (2007) Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66:283–292. https://doi.org/10.1136/ard.2005.051078 PubMedGoogle Scholar
  52. 52.
    Flossmann O, Baslund B, Bruchfeld A et al (2009) Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis. Ann Rheum Dis 68:1125–1130. https://doi.org/10.1136/ard.2008.092429 PubMedCrossRefGoogle Scholar
  53. 53.
    Flossmann O, Berden A, de Groot K et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494. https://doi.org/10.1136/ard.2010.137778 PubMedCrossRefGoogle Scholar
  54. 54.
    Fortin PM, Tejani AM, Bassett K, Musini VM (2013) Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev 1:CD7057. https://doi.org/10.1002/14651858.CD007057.pub3 Google Scholar
  55. 55.
    Gayraud M, Guillevin L, le Toumelin P et al (2001) Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675. https://doi.org/10.1002/1529-0131(200103)44:3〈666::AID-ANR116〉3.0.CO;2-APubMedCrossRefGoogle Scholar
  56. 56.
    Geetha D, Eirin A, True K et al (2011) Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation 91:1370–1375. https://doi.org/10.1097/TP.0b013e31821ab9aa PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Gregersen JW, Kristensen T, Krag SRP et al (2012) Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin Exp Rheumatol 30:S39–S47PubMedGoogle Scholar
  58. 58.
    de Groot K, Gross WL, Herlyn K, Reinhold-Keller E (2001) Development and validation of a disease extent index for Wegener’s granulomatosis. Clin Nephrol 55:31–38PubMedGoogle Scholar
  59. 59.
    De Groot K, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461–2469. https://doi.org/10.1002/art.21142 PubMedCrossRefGoogle Scholar
  60. 60.
    de Groot K, Harper L, Jayne DRW et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680PubMedCrossRefGoogle Scholar
  61. 61.
    Le Guenno G, Mahr A, Pagnoux C et al (2011) Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 63:1435–1445. https://doi.org/10.1002/art.30296 PubMedCrossRefGoogle Scholar
  62. 62.
    Guillevin L, Fain O, Lhote F et al (1992) Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 35:208–215PubMedCrossRefGoogle Scholar
  63. 63.
    Guillevin L, Lhote F, Jarrousse B, Fain O (1992) Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris) 143:405–416Google Scholar
  64. 64.
    Guillevin L, Lhote F, Cohen P et al (1995) Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 38:1638–1645PubMedCrossRefGoogle Scholar
  65. 65.
    Guillevin L, Cordier JF, Lhote F et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40:2187–2198. https://doi.org/10.1002/1529-0131(199712)40:12〈2187::AID-ART12〉3.0.CO;2-HPubMedCrossRefGoogle Scholar
  66. 66.
    Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421–430. https://doi.org/10.1002/1529-0131(199904)42:3〈421::AID-ANR5〉3.0.CO;2-6PubMedCrossRefGoogle Scholar
  67. 67.
    Guillevin L, Pagnoux C, Seror R et al (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90:19–27. https://doi.org/10.1097/MD.0b013e318205a4c6 CrossRefGoogle Scholar
  68. 68.
    Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780. https://doi.org/10.1056/NEJMoa1404231 PubMedCrossRefGoogle Scholar
  69. 69.
    Hagen EC, Daha MR, Hermans J et al (1998) Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 53:743–753. https://doi.org/10.1046/j.1523-1755.1998.00807.x PubMedCrossRefGoogle Scholar
  70. 70.
    Han F, Liu G, Zhang X et al (2011) Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am J Nephrol 33:185–192. https://doi.org/10.1159/000324364 PubMedCrossRefGoogle Scholar
  71. 71.
    Harper L, Morgan MD, Walsh M et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960. https://doi.org/10.1136/annrheumdis-2011-200477 PubMedCrossRefGoogle Scholar
  72. 72.
    Haubitz M, Kliem V, Koch KM et al (1997) Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. Transplantation 63:1251–1257PubMedCrossRefGoogle Scholar
  73. 73.
    Haubitz M, Koch KM, Brunkhorst R (1998) Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 13:2074–2076PubMedCrossRefGoogle Scholar
  74. 74.
    Haubitz M, Schellong S, Göbel U et al (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 41:1835–1844. https://doi.org/10.1002/1529-0131(199810)41:10〈1835::AID-ART16〉3.0.CO;2-QPubMedCrossRefGoogle Scholar
  75. 75.
    Hauer HA, Bajema IM, Van Houwelingen HC et al (2002) Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 62:1732–1742. https://doi.org/10.1046/j.1523-1755.2002.00605.x PubMedCrossRefGoogle Scholar
  76. 76.
    Hazlewood GS, Metzler C, Tomlinson GA et al (2014) Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis. Joint Bone Spine 81:337–341. https://doi.org/10.1016/j.jbspin.2013.11.006 PubMedCrossRefGoogle Scholar
  77. 77.
    Heijl C, Harper L, Flossmann O et al (2011) Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 70:1415–1421. https://doi.org/10.1136/ard.2010.145250 PubMedCrossRefGoogle Scholar
  78. 78.
    Hellmich B, Csernok E, Fredenhagen G, Gross WL (2007) A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol 25:S1–S5PubMedGoogle Scholar
  79. 79.
    Hellmich B, Flossmann O, Gross WL et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617. https://doi.org/10.1136/ard.2006.062711 PubMedCrossRefGoogle Scholar
  80. 80.
    Henes JC, Fritz J, Koch S et al (2007) Rituximab for treatment-resistant extensive Wegener’s granulomatosis—additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 26:1711–1715. https://doi.org/10.1007/s10067-007-0643-9 PubMedCrossRefGoogle Scholar
  81. 81.
    Henes JC, Henes M, von Wolff M et al (2012) Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network. Clin Exp Rheumatol 30:S53–S56PubMedGoogle Scholar
  82. 82.
    Herlyn K, Gross WL, Reinhold-Keller E (2008) Longitudinal effects of structured patient education programs for vasculitis patients. Z Rheumatol 67:206–210. https://doi.org/10.1007/s00393-008-0290-9 PubMedCrossRefGoogle Scholar
  83. 83.
    Herlyn K, Buckert F, Gross WL, Reinhold-Keller E (2014) Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford) 53:882–889. https://doi.org/10.1093/rheumatology/ket440 CrossRefGoogle Scholar
  84. 84.
    Herrmann K, Gross WL, Moosig F (2012) Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol 30:S62–S65PubMedGoogle Scholar
  85. 85.
    Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304:2381–2388. https://doi.org/10.1001/jama.2010.1658 PubMedCrossRefGoogle Scholar
  86. 86.
    Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498PubMedCrossRefGoogle Scholar
  87. 87.
    Hoffman GS, Leavitt RY, Kerr GS, Fauci AS (1992) The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35:1322–1329PubMedCrossRefGoogle Scholar
  88. 88.
    Hoffman GS, Thomas-Golbanov CK, Chan J et al (2003) Treatment of subglottic stenosis, due to Wegener’s granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 30:1017–1021PubMedGoogle Scholar
  89. 89.
    Hogan SL, Nachman PH, Wilkman AS et al (1996) Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:23–32PubMedGoogle Scholar
  90. 90.
    Hogan SL, Falk RJ, Chin H et al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143:621–631PubMedCrossRefGoogle Scholar
  91. 91.
    Holle JU, Hellmich B, Backes M et al (2005) Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off? Ann Rheum Dis 64:1773–1779. https://doi.org/10.1136/ard.2005.035279 PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Holle JU, Gross WL, Holl-Ulrich K et al (2010) Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 69:1934–1939. https://doi.org/10.1136/ard.2010.130203 PubMedCrossRefGoogle Scholar
  93. 93.
    Holle JU, Gross WL, Latza U et al (2011) Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63:257–266. https://doi.org/10.1002/art.27763 PubMedCrossRefGoogle Scholar
  94. 94.
    Holle JU, Dubrau C, Herlyn K et al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71:327–333. https://doi.org/10.1136/ard.2011.153601 PubMedCrossRefGoogle Scholar
  95. 95.
    Holle JU, Herrmann K, Gross WL, Csernok E (2012) Comparative analysis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin Exp Rheumatol 30:S66–S69PubMedGoogle Scholar
  96. 96.
    Holle JU, Voigt C, Both M et al (2013) Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford) 52:875–882. https://doi.org/10.1093/rheumatology/kes382 CrossRefGoogle Scholar
  97. 97.
    Holvast A, Stegeman CA, Benne CA et al (2009) Wegener’s granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 68:873–878. https://doi.org/10.1136/ard.2008.092924 PubMedCrossRefGoogle Scholar
  98. 98.
    Hruskova Z, Casian AL, Konopasek P et al (2013) Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand J Rheumatol 42:211–214. https://doi.org/10.3109/03009742.2012.754939 PubMedCrossRefGoogle Scholar
  99. 99.
    Hruskova Z, Stel VS, Jayne D et al (2015) Characteristics and outcomes of granulomatosis with polyangiitis (Wegener) and microscopic polyangiitis requiring renal replacement therapy: results from the European Renal Association-European Dialysis and Transplant Association Registry. Am J Kidney Dis 66:613–620. https://doi.org/10.1053/j.ajkd.2015.03.025 PubMedCrossRefGoogle Scholar
  100. 100.
    Hseu AF, Benninger MS, Haffey TM, Lorenz R (2014) Subglottic stenosis: a ten-year review of treatment outcomes. Laryngoscope 124:736–741. https://doi.org/10.1002/lary.24410 PubMedCrossRefGoogle Scholar
  101. 101.
    Hu W, Liu C, Xie H et al (2008) Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 23:1307–1312. https://doi.org/10.1093/ndt/gfm780 PubMedCrossRefGoogle Scholar
  102. 102.
    Jarrousse B, Guillevin L, Bindi P et al (1993) Increased risk of Pneumocystis carinii pneumonia in patients with Wegener’s granulomatosis. Clin Exp Rheumatol 11:615–621PubMedGoogle Scholar
  103. 103.
    Jayne D, Rasmussen N, Andrassy K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44. https://doi.org/10.1056/NEJMoa020286 PubMedCrossRefGoogle Scholar
  104. 104.
    Jayne DR, Davies MJ, Fox CJ et al (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137–1139PubMedCrossRefGoogle Scholar
  105. 105.
    Jayne DR, Chapel H, Adu D et al (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439PubMedCrossRefGoogle Scholar
  106. 106.
    Jayne DRW, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188. https://doi.org/10.1681/ASN.2007010090 PubMedCrossRefGoogle Scholar
  107. 107.
    Jeffs LS, Peh CA, Jose MD et al (2015) Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton) 20:343–351. https://doi.org/10.1111/nep.12416 CrossRefGoogle Scholar
  108. 108.
    Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedCrossRefGoogle Scholar
  109. 109.
    Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 65:1–11. https://doi.org/10.1002/art.37715 PubMedCrossRefGoogle Scholar
  110. 110.
    Jones RB, Ferraro AJ, Chaudhry AN et al (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60:2156–2168. https://doi.org/10.1002/art.24637 PubMedCrossRefGoogle Scholar
  111. 111.
    Jones RB, Tervaert JWC, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220. https://doi.org/10.1056/NEJMoa0909169 PubMedCrossRefGoogle Scholar
  112. 112.
    Jones RB, Furuta S, Tervaert JWC et al (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2‑year results of a randomised trial. Ann Rheum Dis 74:1178–1182. https://doi.org/10.1136/annrheumdis-2014-206404 PubMedCrossRefGoogle Scholar
  113. 113.
    Joshi L, Lightman SL, Salama AD et al (2011) Rituximab in refractory ophthalmic Wegener’s granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 118:2498–2503. https://doi.org/10.1016/j.ophtha.2011.06.009 PubMedCrossRefGoogle Scholar
  114. 114.
    Josselin L, Mahr A, Cohen P et al (2008) Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 67:1343–1346. https://doi.org/10.1136/ard.2007.083584 PubMedCrossRefGoogle Scholar
  115. 115.
    Joy MS, Hogan SL, Jennette JC et al (2005) A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 20:2725–2732. https://doi.org/10.1093/ndt/gfi117 PubMedCrossRefGoogle Scholar
  116. 116.
    Kaplan-Pavlovcic S, Cerk K, Kveder R et al (2003) Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant 18(Suppl 5):v5–v7PubMedCrossRefGoogle Scholar
  117. 117.
    Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262–268. https://doi.org/10.1002/art.20718 PubMedCrossRefGoogle Scholar
  118. 118.
    Keogh KA, Ytterberg SR, Fervenza FC et al (2006) Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173:180–187. https://doi.org/10.1164/rccm.200507-1144OC PubMedCrossRefGoogle Scholar
  119. 119.
    Kerr GS, Fleisher TA, Hallahan CW et al (1993) Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis. Arthritis Rheum 36:365–371PubMedCrossRefGoogle Scholar
  120. 120.
    Khan SA, Subla MR, Behl D et al (2007) Outcome of patients with small-vessel vasculitis admitted to a medical ICU. Chest 131:972–976. https://doi.org/10.1378/chest.06-2464 PubMedCrossRefGoogle Scholar
  121. 121.
    Kim S, Marigowda G, Oren E et al (2010) Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 125:1336–1343. https://doi.org/10.1016/j.jaci.2010.03.028 PubMedCrossRefGoogle Scholar
  122. 122.
    Klemmer PJ, Chalermskulrat W, Reif MS et al (2003) Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42:1149–1153PubMedCrossRefGoogle Scholar
  123. 123.
    Kliem V, Haubitz M, Ehlerding G et al (1997) Outcome of kidney transplantation in patients with systemic autoimmune diseases. Transplant Proc 29:957–958PubMedCrossRefGoogle Scholar
  124. 124.
    Knight A, Askling J, Ekbom A (2002) Cancer incidence in a population-based cohort of patients with Wegener’s granulomatosis. Int J Cancer 100:82–85. https://doi.org/10.1002/ijc.10444 PubMedCrossRefGoogle Scholar
  125. 125.
    Knight A, Askling J, Granath F et al (2004) Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 63:1307–1311. https://doi.org/10.1136/ard.2003.019125 PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Goldacker S, Gause AM, Warnatz K, Kommission Pharmakotherapie der DGRh (2013) Vaccination in adult patients with chronic inflammatory rheumatic diseases. Z Rheumatol 72:690–704. https://doi.org/10.1007/s00393-013-1155-4 PubMedCrossRefGoogle Scholar
  127. 127.
    Warnatz K, Goldacker S, Gause AM, Kommission Pharmakotherapie der DGRh (2013) Vaccination recommendations of the Commission for Pharmacotherapy of the German Society of Rheumatology. Z Rheumatol 72:687–689. https://doi.org/10.1007/s00393-013-1154-5 PubMedCrossRefGoogle Scholar
  128. 128.
    Koselj-Kajtna M, Koselj M, Rott T et al (2002) Infectious complications of immunosuppressive treatment for anti-neutrophil cytoplasm antibody-related vasculitis. Transplant Proc 34:3001–3002PubMedCrossRefGoogle Scholar
  129. 129.
    Lamprecht P, Voswinkel J, Lilienthal T et al (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford) 41:1303–1307CrossRefGoogle Scholar
  130. 130.
    Langford CA, Sneller MC, Hallahan CW et al (1996) Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum 39:1754–1760PubMedCrossRefGoogle Scholar
  131. 131.
    Langford CA, Talar-Williams C, Sneller MC (2000) Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43:1836–1840. https://doi.org/10.1002/1529-0131(200008)43:8〈1836::AID-ANR20〉3.0.CO;2-RPubMedCrossRefGoogle Scholar
  132. 132.
    Lanham JG, Elkon KB, Pusey CD, Hughes GR (1984) Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63:65–81CrossRefGoogle Scholar
  133. 133.
    Leavitt RY, Fauci AS, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMedCrossRefGoogle Scholar
  134. 134.
    Li Z‑Y, Gou S‑J, Chen M, Zhao M‑H (2013) Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center. Semin Arthritis Rheum 42:515–521. https://doi.org/10.1016/j.semarthrit.2012.09.005 PubMedCrossRefGoogle Scholar
  135. 135.
    Li Z‑Y, Chang D‑Y, Zhao M‑H, Chen M (2014) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol 66:1920–1926. https://doi.org/10.1002/art.38621 PubMedCrossRefGoogle Scholar
  136. 136.
    de Lind van Wijngaarden RAF, Hauer HA, Wolterbeek R et al (2006) Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 17:2264–2274. https://doi.org/10.1681/ASN.2005080870 PubMedCrossRefGoogle Scholar
  137. 137.
    Lionaki S, Blyth ER, Hogan SL et al (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64:3452–3462. https://doi.org/10.1002/art.34562 PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Little MA, Nightingale P, Verburgh CA et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036–1043. https://doi.org/10.1136/ard.2009.109389 PubMedCrossRefGoogle Scholar
  139. 139.
    de Luna G, Chauveau D, Aniort J et al (2015) Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: data from the French Vasculitis Study Group. J Autoimmun 65:49–55. https://doi.org/10.1016/j.jaut.2015.08.003 PubMedCrossRefGoogle Scholar
  140. 140.
    Mahr A, Girard T, Agher R, Guillevin L (2001) Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology (Oxford) 40:492–498CrossRefGoogle Scholar
  141. 141.
    Mahr A, Batteux F, Tubiana S et al (2014) Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol 66:1672–1677. https://doi.org/10.1002/art.38389 PubMedCrossRefGoogle Scholar
  142. 142.
    Marco H, Mirapeix E, Arcos E et al (2013) Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transplant 27:338–347. https://doi.org/10.1111/ctr.12084 PubMedCrossRefGoogle Scholar
  143. 143.
    Martinez Del Pero M, Chaudhry A, Jones RB et al (2009) B‑cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study. Clin Otolaryngol 34:328–335. https://doi.org/10.1111/j.1749-4486.2009.01968.x PubMedCrossRefGoogle Scholar
  144. 144.
    Martinez V, Cohen P, Pagnoux C et al (2008) Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 58:308–317. https://doi.org/10.1002/art.23147 PubMedCrossRefGoogle Scholar
  145. 145.
    Masi AT, Hunder GG, Lie JT et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100PubMedCrossRefGoogle Scholar
  146. 146.
    Matteson EL, Gold KN, Bloch DA, Hunder GG (1996) Long-term survival of patients with Wegener’s granulomatosis from the American College of Rheumatology Wegener’s Granulomatosis Classification Criteria Cohort. Am J Med 101:129–134PubMedCrossRefGoogle Scholar
  147. 147.
    McDermott EM, Powell RJ (1996) Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 55:224–229PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    McGregor JG, Hogan SL, Hu Y et al (2012) Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 7:240–247. https://doi.org/10.2215/CJN.05610611 PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    McKinney EF, Lyons PA, Carr EJ et al (2010) A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 16:586–591. https://doi.org/10.1038/nm.2130 PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Mekhail TM, Hoffman GS (2000) Longterm outcome of Wegener’s granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 27:1237–1240PubMedGoogle Scholar
  151. 151.
    de Menthon M, Cohen P, Pagnoux C et al (2011) Infliximab or rituximab for refractory Wegener’s granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 29:S63–S71PubMedGoogle Scholar
  152. 152.
    Merkel PA, Lo GH, Holbrook JT et al (2005) Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142:620–626PubMedCrossRefGoogle Scholar
  153. 153.
    Merkel PA, Cuthbertson DD, Hellmich B et al (2009) Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 68:103–106. https://doi.org/10.1136/ard.2008.097758 PubMedCrossRefGoogle Scholar
  154. 154.
    Metzler C, Hellmich B, Gause A et al (2004) Churg Strauss syndrome—successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22:S52–S61PubMedGoogle Scholar
  155. 155.
    Metzler C, Miehle N, Manger K et al (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford) 46:1087–1091. https://doi.org/10.1093/rheumatology/kem029 CrossRefGoogle Scholar
  156. 156.
    Metzler C, Schnabel A, Gross WL, Hellmich B (2008) A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 26:S35–S40PubMedGoogle Scholar
  157. 157.
    Metzler C, Csernok E, Gross WL, Hellmich B (2010) Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol 28:24–30PubMedGoogle Scholar
  158. 158.
    Miloslavsky EM, Specks U, Merkel PA et al (2013) Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 65:2441–2449. https://doi.org/10.1002/art.38044 PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Miloslavsky EM, Specks U, Merkel PA et al (2014) Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 66:3151–3159. https://doi.org/10.1002/art.38788 PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Miloslavsky EM, Specks U, Merkel PA et al (2015) Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol 67:1629–1636. https://doi.org/10.1002/art.39104 PubMedCrossRefGoogle Scholar
  161. 161.
    Mohammad AJ, Hot A, Arndt F et al (2014) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2014-206095 Google Scholar
  162. 162.
    Monach PA, Arnold LM, Merkel PA (2010) Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 62:9–21. https://doi.org/10.1002/art.25061 PubMedCrossRefGoogle Scholar
  163. 163.
    Moosig F, Gross WL, Herrmann K et al (2011) Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 155:341–343. https://doi.org/10.7326/0003-4819-155-5-201109060-00026 PubMedCrossRefGoogle Scholar
  164. 164.
    Moosig F, Bremer JP, Hellmich B et al (2013) A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 72:1011–1017. https://doi.org/10.1136/annrheumdis-2012-201531 PubMedCrossRefGoogle Scholar
  165. 165.
    Moran S, Little MA (2014) Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol 26:37–41. https://doi.org/10.1097/BOR.0000000000000006 PubMedCrossRefGoogle Scholar
  166. 166.
    Morgan MD, Turnbull J, Selamet U et al (2009) Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 60:3493–3500. https://doi.org/10.1002/art.24957 PubMedCrossRefGoogle Scholar
  167. 167.
    Morgan MD, Drayson MT, Savage COS, Harper L (2011) Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract 117:c89–c97. https://doi.org/10.1159/000319655 PubMedCrossRefGoogle Scholar
  168. 168.
    Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310–317. https://doi.org/10.1136/ard.2008.088096 PubMedCrossRefGoogle Scholar
  169. 169.
    Muso E, Ito-Ihara T, Ono T et al (2004) Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis 57:S17–S18PubMedGoogle Scholar
  170. 170.
    Nachman PH, Hogan SL, Jennette JC, Falk RJ (1996) Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:33–39PubMedGoogle Scholar
  171. 171.
    Nasrallah M, Pouliot Y, Hartmann B et al (2015) Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment. Arthritis Res Ther 17:262. https://doi.org/10.1186/s13075-015-0778-z PubMedPubMedCentralCrossRefGoogle Scholar
  172. 172.
    Nouraei SAR, Obholzer R, Ind PW et al (2008) Results of endoscopic surgery and intralesional steroid therapy for airway compromise due to tracheobronchial Wegener’s granulomatosis. Thorax 63:49–52. https://doi.org/10.1136/thx.2007.078915 PubMedCrossRefGoogle Scholar
  173. 173.
    Novack SN, Pearson CM (1971) Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 284:938–942. https://doi.org/10.1056/NEJM197104292841703 PubMedCrossRefGoogle Scholar
  174. 174.
    Novikov P, Moiseev S, Smitienko I, Zagvozdkina E (2016) Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: a report of 6 cases. Joint Bone Spine 83:81–84. https://doi.org/10.1016/j.jbspin.2015.04.016 PubMedCrossRefGoogle Scholar
  175. 175.
    Ntatsaki E, Carruthers D, Chakravarty K et al (2014) BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53:2306–2309. https://doi.org/10.1093/rheumatology/ket445 CrossRefGoogle Scholar
  176. 176.
    Nyberg G, Akesson P, Nordén G, Wieslander J (1997) Kidney transplantation in patients with systemic vasculitis. Transplant Proc 29:235PubMedCrossRefGoogle Scholar
  177. 177.
    Ognibene FP, Shelhamer JH, Hoffman GS et al (1995) Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. Am J Respir Crit Care Med 151:795–799. https://doi.org/10.1164/ajrccm/151.3_Pt_1.795 PubMedGoogle Scholar
  178. 178.
    Omdal R, Wildhagen K, Hansen T et al (2005) Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand J Rheumatol 34:229–232PubMedCrossRefGoogle Scholar
  179. 179.
    Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790–2803. https://doi.org/10.1056/NEJMoa0802311 PubMedCrossRefGoogle Scholar
  180. 180.
    Pagnoux C, Carette S, Khalidi NA et al (2015) Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33:77–83Google Scholar
  181. 181.
    Pagnoux C, Quéméneur T, Ninet J et al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 67:1117–1127. https://doi.org/10.1002/art.39011 PubMedCrossRefGoogle Scholar
  182. 182.
    Pankhurst T, Savage COS, Gordon C, Harper L (2004) Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) 43:1532–1535. https://doi.org/10.1093/rheumatology/keh374 CrossRefGoogle Scholar
  183. 183.
    Pendergraft WF, Cortazar FB, Wenger J et al (2014) Long-term maintenance therapy using rituximab-induced continuous B‑cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 9:736–744. https://doi.org/10.2215/CJN.07340713 PubMedPubMedCentralCrossRefGoogle Scholar
  184. 184.
    Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C et al (2010) Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 49:2181–2190. https://doi.org/10.1093/rheumatology/keq244 CrossRefGoogle Scholar
  185. 185.
    Pons-Estel GJ, Salerni GE, Serrano RM et al (2011) Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev 10:679–684. https://doi.org/10.1016/j.autrev.2011.04.028 PubMedCrossRefGoogle Scholar
  186. 186.
    Puéchal X, Pagnoux C, Perrodeau É et al (2016) Long-term outcomes among participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis. Arthritis Rheumatol 68:690–701. https://doi.org/10.1002/art.39450 PubMedCrossRefGoogle Scholar
  187. 187.
    Qian SY, Malata CM (2014) Avoiding pitfalls in open augmentation rhinoplasty with autologous L‑shaped costal cartilage strut grafts for saddle nose collapse due to autoimmune disease: the Cambridge experience. J Plast Reconstr Aesthetic Surg 67:e195–e203. https://doi.org/10.1016/j.bjps.2014.03.029 CrossRefGoogle Scholar
  188. 188.
    Radice A, Bianchi L, Maggiore U et al (2013) Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegener’s). Clin Chem Lab Med 51:2141–2149. https://doi.org/10.1515/cclm-2013-0308 PubMedCrossRefGoogle Scholar
  189. 189.
    Rahmattulla C, Berden AE, Wakker S‑C et al (2015) Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013. Arthritis Rheumatol 67:3270–3278. https://doi.org/10.1002/art.39317 PubMedCrossRefGoogle Scholar
  190. 190.
    Rasmussen N, Salmela A, Ekstrand A et al (2013) Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener’s) may reflect treatment rather than disease activity. Clin Exp Rheumatol 31:S38–S44PubMedGoogle Scholar
  191. 191.
    Reinhold-Keller E, De Groot K, Rudert H et al (1996) Response to trimethoprim/sulfamethoxazole in Wegener’s granulomatosis depends on the phase of disease. QJM 89:15–23PubMedCrossRefGoogle Scholar
  192. 192.
    Rhee RL, Hogan SL, Poulton CJ et al (2016) Trends in long-term outcomes among patients with ANCA-associated vasculitis with renal disease. Arthritis Rheumatol. https://doi.org/10.1002/art.39614 PubMedPubMedCentralGoogle Scholar
  193. 193.
    Ribi C, Cohen P, Pagnoux C et al (2008) Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58:586–594. https://doi.org/10.1002/art.23198 PubMedCrossRefGoogle Scholar
  194. 194.
    Ribi C, Cohen P, Pagnoux C et al (2010) Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62:1186–1197. https://doi.org/10.1002/art.27340 PubMedCrossRefGoogle Scholar
  195. 195.
    Robson J, Doll H, Suppiah R et al (2015) Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 54:471–481. https://doi.org/10.1093/rheumatology/keu366 CrossRefGoogle Scholar
  196. 196.
    Robson J, Doll H, Suppiah R et al (2015) Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 74:177–184. https://doi.org/10.1136/annrheumdis-2013-203927 PubMedCrossRefGoogle Scholar
  197. 197.
    Roccatello D, Baldovino S, Alpa M et al (2008) Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 26:67–71Google Scholar
  198. 198.
    Roll P, Ostermeier E, Haubitz M et al (2012) Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol 39:2153–2156. https://doi.org/10.3899/jrheum.120482 PubMedCrossRefGoogle Scholar
  199. 199.
    Romeu M, Couchoud C, Delarozière J‑C et al (2014) Survival of patients with ANCA-associated vasculitis on chronic dialysis: data from the French REIN registry from 2002 to 2011. QJM 107:545–555. https://doi.org/10.1093/qjmed/hcu043 PubMedCrossRefGoogle Scholar
  200. 200.
    Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N et al (2012) Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 39:125–130. https://doi.org/10.3899/jrheum.110143 PubMedCrossRefGoogle Scholar
  201. 201.
    Sablé-Fourtassou R, Cohen P, Mahr A et al (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143:632–638PubMedCrossRefGoogle Scholar
  202. 202.
    Samson M, Puéchal X, Devilliers H et al (2013) Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 43:60–69. https://doi.org/10.1016/j.jaut.2013.03.003 PubMedCrossRefGoogle Scholar
  203. 203.
    Savige J, Gillis D, Benson E et al (1999) International consensus statement on testing and reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 111:507–513PubMedCrossRefGoogle Scholar
  204. 204.
    Savige J, Dimech W, Fritzler M et al (2003) Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 120:312–318. https://doi.org/10.1309/WAEP-ADW0-K4LP-UHFN PubMedCrossRefGoogle Scholar
  205. 205.
    Schirmer JH, Wright MN, Vonthein R et al (2015) Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kev286 Google Scholar
  206. 206.
    Schmitt WH, Hagen EC, Neumann I et al (2004) Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65:1440–1448. https://doi.org/10.1111/j.1523-1755.2004.00534.x PubMedCrossRefGoogle Scholar
  207. 207.
    Schmitt WH, Birck R, Heinzel PA et al (2005) Prolonged treatment of refractory Wegener’s granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 20:1083–1092. https://doi.org/10.1093/ndt/gfh763 PubMedCrossRefGoogle Scholar
  208. 208.
    Schnabel A, Holl-Ulrich K, Dalhoff K et al (1997) Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J 10:2738–2743PubMedCrossRefGoogle Scholar
  209. 209.
    Schokkenbroek AA, Franssen CFM, Dikkers FG (2008) Dilatation tracheoscopy for laryngeal and tracheal stenosis in patients with Wegener’s granulomatosis. Eur Arch Otorhinolaryngol 265:549–555. https://doi.org/10.1007/s00405-007-0518-3 PubMedCrossRefGoogle Scholar
  210. 210.
    Schultz H, Csernok E, Herlyn K et al (2003) ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations. Clin Exp Rheumatol 21:117–120Google Scholar
  211. 211.
    Seo P, Min Y‑I, Holbrook JT et al (2005) Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 52:2168–2178. https://doi.org/10.1002/art.21117 PubMedCrossRefGoogle Scholar
  212. 212.
    Seo P, Specks U, Keogh KA (2008) Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol 35:2017–2023PubMedGoogle Scholar
  213. 213.
    Sepehr A, Alexander AJ, Chauhan N, Gantous A (2011) Detailed analysis of graft techniques for nasal reconstruction following Wegener granulomatosis. J Otolaryngol 40:473–480Google Scholar
  214. 214.
    Seror R, Pagnoux C, Ruivard M et al (2010) Treatment strategies and outcome of induction-refractory Wegener’s granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis 69:2125–2130. https://doi.org/10.1136/ard.2010.131953 PubMedCrossRefGoogle Scholar
  215. 215.
    Silva F, Specks U, Kalra S et al (2010) Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement – A prospective, open-label pilot trial. Clin J Am Soc Nephrol 5:445–453. https://doi.org/10.2215/CJN.06010809 PubMedPubMedCentralCrossRefGoogle Scholar
  216. 216.
    Sinico RA, Di Toma L, Maggiore U et al (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52:2926–2935. https://doi.org/10.1002/art.21250 PubMedCrossRefGoogle Scholar
  217. 217.
    Smith RM, Jones RB, Guerry M‑J et al (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3760–3769. https://doi.org/10.1002/art.34583 PubMedCrossRefGoogle Scholar
  218. 218.
    Specks U, Merkel PA, Seo P et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:417–427. https://doi.org/10.1056/NEJMoa1213277 PubMedCrossRefGoogle Scholar
  219. 219.
    Springer J, Nutter B, Langford CA et al (2014) Granulomatosis with polyangiitis (Wegener’s): impact of maintenance therapy duration. Medicine (Baltimore) 93:82–90. https://doi.org/10.1097/MD.0000000000000020 CrossRefGoogle Scholar
  220. 220.
    Stassen PM, Tervaert JWC, Stegeman CA (2007) Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 66:798–802. https://doi.org/10.1136/ard.2006.060301 PubMedCrossRefGoogle Scholar
  221. 221.
    Stassen PM, Derks RPH, Kallenberg CGM, Stegeman CA (2008) Venous thromboembolism in ANCA-associated vasculitis—incidence and risk factors. Rheumatology (Oxford) 47:530–534. https://doi.org/10.1093/rheumatology/ken035 CrossRefGoogle Scholar
  222. 222.
    Stassen PM, Sanders J‑S, Kallenberg CGM, Stegeman CA (2008) Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 23:654–658. https://doi.org/10.1093/ndt/gfm640 PubMedCrossRefGoogle Scholar
  223. 223.
    Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16–20. https://doi.org/10.1056/NEJM199607043350103 PubMedCrossRefGoogle Scholar
  224. 224.
    Stern A, Green H, Paul M et al (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10:CD5590. https://doi.org/10.1002/14651858.CD005590.pub3 Google Scholar
  225. 225.
    Stone JH, Tun W, Hellman DB (1999) Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 26:1134–1139PubMedGoogle Scholar
  226. 226.
    Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232. https://doi.org/10.1056/NEJMoa0909905 PubMedPubMedCentralCrossRefGoogle Scholar
  227. 227.
    Strehl C, Bijlsma JWJ, de Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952–957. https://doi.org/10.1136/annrheumdis-2015-208916 PubMedCrossRefGoogle Scholar
  228. 228.
    Suppiah R, Judge A, Batra R et al (2011) A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res 63:588–596. https://doi.org/10.1002/acr.20433 CrossRefGoogle Scholar
  229. 229.
    Szczeklik W, Sokołowska BM, Zuk J et al (2011) The course of asthma in Churg-Strauss syndrome. J Asthma 48:183–187. https://doi.org/10.3109/02770903.2010.551796 PubMedCrossRefGoogle Scholar
  230. 230.
    Szpirt WM, Heaf JG, Petersen J (2011) Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis—a clinical randomized controlled trial. Nephrol Dial Transplant 26:206–213. https://doi.org/10.1093/ndt/gfq360 PubMedCrossRefGoogle Scholar
  231. 231.
    Takizawa Y, Inokuma S, Tanaka Y et al (2008) Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology (Oxford) 47:1373–1378. https://doi.org/10.1093/rheumatology/ken231 CrossRefGoogle Scholar
  232. 232.
    Talar-Williams C, Hijazi YM, Walther MM et al (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124:477–484PubMedCrossRefGoogle Scholar
  233. 233.
    Tanna A, Guarino L, Tam FWK et al (2015) Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant 30:1185–1192. https://doi.org/10.1093/ndt/gfu237 PubMedCrossRefGoogle Scholar
  234. 234.
    Tatsis E, Schnabel A, Gross WL (1998) Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 129:370–374PubMedCrossRefGoogle Scholar
  235. 235.
    Taylor SRJ, Salama AD, Joshi L et al (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum 60:1540–1547. https://doi.org/10.1002/art.24454 PubMedCrossRefGoogle Scholar
  236. 236.
    Tesfa D, Ajeganova S, Hägglund H et al (2011) Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 63:2209–2214. https://doi.org/10.1002/art.30427 PubMedCrossRefGoogle Scholar
  237. 237.
    Thiel J, Hässler F, Salzer U et al (2013) Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 15:R133. https://doi.org/10.1186/ar4313 PubMedPubMedCentralCrossRefGoogle Scholar
  238. 238.
    Tomasson G, Boers M, Walsh M et al (2012) Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res 64:273–279. https://doi.org/10.1002/acr.20649 CrossRefGoogle Scholar
  239. 239.
    Tomasson G, Grayson PC, Mahr AD et al (2012) Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. Rheumatology (Oxford) 51:100–109. https://doi.org/10.1093/rheumatology/ker280 CrossRefGoogle Scholar
  240. 240.
    Travis WD, Hoffman GS, Leavitt RY et al (1991) Surgical pathology of the lung in Wegener’s granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 15:315–333PubMedCrossRefGoogle Scholar
  241. 241.
    Tsurikisawa N, Taniguchi M, Saito H et al (2004) Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92:80–87. https://doi.org/10.1016/S1081-1206(10)61714-0 PubMedCrossRefGoogle Scholar
  242. 242.
    Turner-Stokes T, Sandhu E, Pepper RJ et al (2014) Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Rheumatology (Oxford) 53:1395–1403. https://doi.org/10.1093/rheumatology/ket489 CrossRefGoogle Scholar
  243. 243.
    Tzelepis GE, Kokosi M, Tzioufas A et al (2010) Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 36:116–121. https://doi.org/10.1183/09031936.00110109 PubMedCrossRefGoogle Scholar
  244. 244.
    Unizony S, Villarreal M, Miloslavsky EM et al (2015) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2015-208073 PubMedPubMedCentralGoogle Scholar
  245. 245.
    Vergunst CE, van Gurp E, Hagen EC et al (2003) An index for renal outcome in ANCA-associated glomerulonephritis. Am J Kidney Dis 41:532–538. https://doi.org/10.1053/ajkd.2003.50115 PubMedCrossRefGoogle Scholar
  246. 246.
    Villa-Forte A, Clark TM, Gomes M et al (2007) Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 86:269–277. https://doi.org/10.1097/MD.0b013e3181568ec0 CrossRefGoogle Scholar
  247. 247.
    Vital C, Vital A, Canron M‑H et al (2006) Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases. J Peripher Nerv Syst 11:20–29. https://doi.org/10.1111/j.1085-9489.2006.00060.x PubMedCrossRefGoogle Scholar
  248. 248.
    Wallace ZS, Lu N, Unizony S et al (2016) Improved survival in granulomatosis with polyangiitis: a general population-based study. Semin Arthritis Rheum 45:483–489. https://doi.org/10.1016/j.semarthrit.2015.07.009 PubMedCrossRefGoogle Scholar
  249. 249.
    Walsh M, Chaudhry A, Jayne D (2008) Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 67:1322–1327. https://doi.org/10.1136/ard.2007.081661 PubMedCrossRefGoogle Scholar
  250. 250.
    Walsh M, Merkel PA, Mahr A, Jayne D (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 62:1166–1173. https://doi.org/10.1002/acr.20176 CrossRefGoogle Scholar
  251. 251.
    Walsh M, Catapano F, Szpirt W et al (2011) Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 57:566–574. https://doi.org/10.1053/j.ajkd.2010.10.049 PubMedCrossRefGoogle Scholar
  252. 252.
    Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548. https://doi.org/10.1002/art.33361 PubMedCrossRefGoogle Scholar
  253. 253.
    Walsh M, Casian A, Flossmann O et al (2013) Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 84:397–402. https://doi.org/10.1038/ki.2013.131 PubMedCrossRefGoogle Scholar
  254. 254.
    Walsh M, Merkel PA, Peh CA et al (2013) Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14:73. https://doi.org/10.1186/1745-6215-14-73 PubMedPubMedCentralCrossRefGoogle Scholar
  255. 255.
    Watts R, Lane S, Hanslik T et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227. https://doi.org/10.1136/ard.2006.054593 PubMedCrossRefGoogle Scholar
  256. 256.
    Wester JL, Clayburgh DR, Stott WJ et al (2011) Airway reconstruction in Wegener’s granulomatosis-associated laryngotracheal stenosis. Laryngoscope 121:2566–2571. https://doi.org/10.1002/lary.22367 PubMedCrossRefGoogle Scholar
  257. 257.
    Wiesner O, Russell KA, Lee AS et al (2004) Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 50:2954–2965. https://doi.org/10.1002/art.20479 PubMedCrossRefGoogle Scholar
  258. 258.
    Zycinska K, Romanowska M, Nowak I et al (2007) Antibody response to inactivated subunit influenza vaccine in patients with Wegener’s granulomatosis. J Physiol Pharmacol 58(Suppl 5):819–828PubMedGoogle Scholar

Copyright information

© Deutsche Gesellschaft für Rheumatologie e.V. Published by Springer Medizin Verlag GmbH. All rights reserved  2017

Authors and Affiliations

  • Jan Henrik Schirmer
    • 1
  • Peer M. Aries
    • 2
  • Kirsten de Groot
    • 3
    • 4
  • Bernhard Hellmich
    • 5
  • Julia U. Holle
    • 6
  • Christian Kneitz
    • 7
  • Ina Kötter
    • 8
  • Peter Lamprecht
    • 9
  • Ulf Müller-Ladner
    • 10
  • Eva Reinhold-Keller
    • 11
  • Christof Specker
    • 12
  • Michael Zänker
    • 13
    • 14
  • Frank Moosig
    • 6
  1. 1.Klinik für Innere Medizin IUniversitätsklinikum Schleswig-Holstein, Campus KielKielDeutschland
  2. 2.Rheumatologie im StruenseehausHamburgDeutschland
  3. 3.Medizinische Klinik IIISana Klinikum OffenbachOffenbachDeutschland
  4. 4.KfH Nierenzentrum OffenbachOffenbachDeutschland
  5. 5.Klinik für Innere Medizin, Rheumatologie und Immunologie, Vaskulitiszentrum SüdMedius Klinik KirchheimKirchheimDeutschland
  6. 6.Rheumazentrum Schleswig-Holstein MitteNeumünsterDeutschland
  7. 7.Klinik für Innere Medizin II, Rheumatologie, klinische Immunologie und GeriatrieKlinikum SüdstadtRostockDeutschland
  8. 8.Abteilung für Rheumatologie, klinische Immunologie und NephrologieAsklepios Klinikum AltonaHamburgDeutschland
  9. 9.Klinik für Rheumatologie und klinische ImmunologieUniversität zu LübeckLübeckDeutschland
  10. 10.Abteilung für Rheumatologie und Klinische Immunologie, Campus KerckhoffJustus-Liebig Universität GiessenBad NauheimDeutschland
  11. 11.Klinik für Rheumatologie und klinische ImmunologieKlinikum Bad BramstedtBad BramstedtDeutschland
  12. 12.Klinik für Rheumatologie und klinische ImmunologieUniversitätsmedizin Essen, St. Josef Krankenhaus WerdenEssenDeutschland
  13. 13.Abteilung für Innere MedizinImmanuel Klinikum Bernau Herzzentrum BrandenburgBernauDeutschland
  14. 14.Medizinische Hochschule BrandenburgNeuruppinDeutschland

Personalised recommendations